General
Preferred name
CABAZITAXEL
Synonyms
XRP6258 ()
RPR-116258A ()
TXD 258 ()
taxoid XRP6258 ()
Jevtana ()
CabazitaxelJEVTANAXRP6258 ()
Cabazitaxel (XRP6258) ()
RPR-116258A, TXD 258, Taxoid XRP6258 ()
Cabazitaxel acetonate ()
NSC-761432 ()
TXD258 ()
TXD-258 ()
Cabazitaxel accord ()
XRP-6258 ()
XRP 6258 ()
Jevtana Kit ()
Cabazitaxel-d9 ()
P&D ID
PD004087
CAS
183133-96-2
1383572-19-7
Tags
available
drug
Approved by
EMA
FDA
First approval
2010
Drug indication
dedifferentiated liposarcoma
Solid tumour/cancer
Breast cancer
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Cabazitaxel is a pan tubulin inhibitor of the taxane class of compounds.
(GtoPdb)
TOXICITY
Cabazitaxel may cause serious side effects including neutropenia, hypersensitivity reactions, gastrointestinal symptoms, and renal failure. Anticipated complications of overdose include exacerbation of adverse reactions such as bone marrow suppression and gastrointestinal disorders. Cabazitaxel penetrates the blood-brain barrier.; LD50, rat = 500 mg/kg
DESCRIPTION
Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.
PRICE
42
DESCRIPTION
Cabazitaxel (taxoid XRP6258) is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
14
Organisms
0
Compound Sets
23
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Nuisance compounds in cellular assays
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
150
Molecular Weight
835.38
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
3
Rotatable Bonds
10
Ring Count
6
Aromatic Ring Count
2
cLogP
4.57
TPSA
202.45
Fraction CSP3
0.58
Chiral centers
11.0
Largest ring
8.0
QED
0.17
Structural alerts
1
Tubulin modulation
Nuisance compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
Cytoskeletal Signaling
Cell Cycle/DNA Damage
cytoskeleton
Indication
prostate cancer
Target
TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8
Autophagy,Microtubule Associated
Microtubule/Tubulin
Microtubule
MOA
microtubule inhibitor
Biosynthetic Origin
Terpenoid, Peptide (NRPS)
Therapeutic Indication
Anticancer
Source data

